MURALI KRISHNA
PRAHALAD

Ph.D., President & CEO, Epic Sciences

Dr. Prahalad is President and CEO of Epic Sciences, Inc. (EPIC), a venture backed company specializing in the detection and characterization of circulating tumor cells (CTCs). 

Prior to joining EPIC, Dr. Prahalad held various roles at Life Technologies Corporation, a global leader in reagents and instruments for biomedical research.  His final role at Life Technologies was VP, Corporate Strategy.  Prior to joining Life Technologies, Dr. Prahalad was VP of Business Development for Sequenom, Inc.

Dr. Prahalad received his B.Sc. with Honors from the University of Michigan and Doctorate in Biochemistry & Molecular Pharmacology from Harvard University.

 

Session: Liquid Biopsy – Using the Right Tool for the Right Job

Liquid biopsy has captured the imagination of investors and the mainstream press alike.  While the ability to assess patients non-invasively is appealing to physicians and patients, there remains much confusion regarding the capabilities and limitations of various technologies.  This session will provide meaningful data and debate on the clinical utility of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes.  Companies representing each technology will present and answer audience questions regarding what some estimates forecast to be a $10BN diagnostic industry.

Web Analytics